Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock

NASDAQ: CYCCPHealthcare / Biotechnology / -
5.06+0.4000+8.56%Vol 2001Y Perf -22.78%
Jul 19th, 2019 18:55
BID4.70 ASK5.88
Open5.27 Previous Close4.66
Pre-Market- After-Trading-
 - -%  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potencial %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/- 
Value Ranking
★★★+ —    54.41
Insiders Value % 3/6/12M
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-/-/- 
Income Ranking
★★★★★ —    77.16
Market Cap (mil)- 
Earnings Rating
Buy
Price Range Ratio 52wk %
23.62 
Earnings Date
-

Today's Price Range

5.065.27

52wk Range

4.467.00

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-5.42%
1 Month
3.27%
3 Months
-3.62%
6 Months
-9.64%
1 Year
-22.78%
3 Years
-20.81%
5 Years
-28.46%
10 Years
354.87%

Name / TickerPriceChg.Chg.%
CYCCP5.060.40008.56
AAPL207.224.63002.29
GOOG1 138.077.97000.71
MSFT138.431.81001.32
XOM75.070.08000.11
WFC46.480.45000.98
JNJ128.64-1.6700-1.28
FB202.323.96002.00
GE10.210.17001.69
JPM114.270.73000.64
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume200
Shares Outstanding (in ths.)0
Trades Count0
Dollar Volume0
Avg. Volume1 063
Avg. Weekly Volume360
Avg. Monthly Volume715
Avg. Quarterly Volume542
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Rating---

Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. The company earns the majority of its revenue from the United Kingdom.

CEO: Spiro Rombotis

Teplephone: +1 908 517-7330

Address: 200 Connell Drive, Berkeley Heights 07922, NJ, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

44%56%

Bearish Bullish

61%39%

News